Literature DB >> 19229698

Extraction of erythrocyte enzymes for the preparation of polyhemoglobin-catalase-superoxide dismutase.

Jingsong Gu1, Thomas Ming Swi Chang.   

Abstract

In sustained severe ischemia, reperfusion with oxygen carriers may result in ischemia-reperfusion injuries because of the release of damaging oxygen radicals. A nanobiotechnology-based polyhemogloin-calatase-superoxide dismutase can prevent this because the oxygen carrier, polyhemoglobin, is linked to antioxidant enzymes, catalase and superoxide dismutase. However, these antioxidant enzymes come from nonhuman sources and recombinant human enzymes are expensive. This paper describes our study on extracting these enzymes from red blood cells and analyzing the amount of enzymes needed for adequate protection from ischemia-reperfusion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19229698      PMCID: PMC3518480          DOI: 10.1080/10731190902742240

Source DB:  PubMed          Journal:  Artif Cells Blood Substit Immobil Biotechnol        ISSN: 1073-1199


  11 in total

Review 1.  Nanobiotechnology for hemoglobin-based blood substitutes.

Authors:  T M S Chang
Journal:  Crit Care Clin       Date:  2009-04       Impact factor: 3.598

2.  Nanobiotechnological modification of hemoglobin and enzymes from this laboratory.

Authors:  Thomas Ming Swi Chang
Journal:  Biochim Biophys Acta       Date:  2008-06-17

3.  Stabilisation of enzymes by microencapsulation with a concentrated protein solution or by microencapsulation followed by cross-linking with glutaraldehyde.

Authors:  T M Chang
Journal:  Biochem Biophys Res Commun       Date:  1971-09-17       Impact factor: 3.575

4.  Isolation and characterization of superoxide dismutase.

Authors:  J V Bannister; W H Bannister
Journal:  Methods Enzymol       Date:  1984       Impact factor: 1.600

5.  Superoxide dismutase: improved assays and an assay applicable to acrylamide gels.

Authors:  C Beauchamp; I Fridovich
Journal:  Anal Biochem       Date:  1971-11       Impact factor: 3.365

6.  The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable.

Authors:  Steven A Gould; Ernest E Moore; David B Hoyt; Paul M Ness; Edward J Norris; Jeffrey L Carson; George A Hides; Ian H G Freeman; Richard DeWoskin; Gerald S Moss
Journal:  J Am Coll Surg       Date:  2002-10       Impact factor: 6.113

Review 7.  First-generation blood substitutes: what have we learned? Biochemical and physiological perspectives.

Authors:  Abdu I Alayash; Felice D'Agnillo; Paul W Buehler
Journal:  Expert Opin Biol Ther       Date:  2007-05       Impact factor: 4.388

8.  Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial.

Authors:  Ernest E Moore; Frederick A Moore; Timothy C Fabian; Andrew C Bernard; Gerard J Fulda; David B Hoyt; Therese M Duane; Leonard J Weireter; Gerardo A Gomez; Mark D Cipolle; George H Rodman; Mark A Malangoni; George A Hides; Laurel A Omert; Steven A Gould
Journal:  J Am Coll Surg       Date:  2008-11-07       Impact factor: 6.113

9.  Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine.

Authors:  P Fossati; L Prencipe; G Berti
Journal:  Clin Chem       Date:  1980-02       Impact factor: 8.327

10.  Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties.

Authors:  F D'Agnillo; T M Chang
Journal:  Nat Biotechnol       Date:  1998-07       Impact factor: 54.908

View more
  4 in total

1.  Towards the development of hemerythrin-based blood substitutes.

Authors:  Augustin C Mot; Alina Roman; Iulia Lupan; Donald M Kurtz; Radu Silaghi-Dumitrescu
Journal:  Protein J       Date:  2010-08       Impact factor: 2.371

2.  The immunological properties of stroma-free polyhemolysate containing catalase and superoxide dismutase activities prepared by polymerized bovine stroma-free hemolysate.

Authors:  Hongli Zhu; Qianqian Du; Chao Chen; Thomas Ming Swi Chang
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2010-04

Review 3.  Blood replacement with nanobiotechnologically engineered hemoglobin and hemoglobin nanocapsules.

Authors:  Thomas Ming Swi Chang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 Jul-Aug

4.  A novel nanobiotherapeutic poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] with no cardiac toxicity for the resuscitation of a rat model with 90 minutes of sustained severe hemorrhagic shock with loss of 2/3 blood volume.

Authors:  Yuzhu Bian; Thomas Ming Swi Chang
Journal:  Artif Cells Nanomed Biotechnol       Date:  2014-10-09       Impact factor: 5.678

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.